INTRODUCTION
============

CD4^-^CD8^-^ double negative (DN) T cells compose approximately 1--3% of total T cells in both mice and humans ([@B63]; [@B1]; [@B25]). Phenotypically, this rare T cell subset expresses a polyclonal αβT cell receptor (TCR) repertoire, lacks the expression of Foxp3 as well as natural killer (NK) cell markers and mostly presents with a naïve T cell phenotype (recently reviewed; [@B34]). Interestingly, their distinct phenotype, namely the lack of CD4 and CD8 co-receptors, is also believed to influence the method by which DN T cells recognize antigens and subsequently signal through their TCR. In fact, major histocompatibility complex (MHC) restriction is the cardinal feature of antigen recognition by T cells, where the CD4 and CD8 co-receptors respectively facilitate the interaction with MHC class II and I molecules. As DN T cells lack both CD4 and CD8 co-receptors, the means by which the αβTCR on the DN T cell recognizes MHC ligands with sufficient affinity and avidity to provide activation of DN T cells is unclear. It has been recently proposed that DN T cells recognize non-MHC ligands. Indeed, using quad-deficient mice that lack the expression of CD4 and CD8 co-receptors as well as MHC class I and II expression, [@B68] demonstrated that T cell development could proceed in an MHC-independent manner. In fact, in the absence of CD4 or CD8 co-receptor expression, the intracellular tyrosine kinase Lck is no longer sequestered by the co-receptors and is thus available to promote MHC-independent TCR signaling in thymocytes. Subsequently, these thymocytes develop into mature DN T cells that enter the periphery ([@B68]). The ability of DN T cells to recognize non-MHC ligands is also supported by the finding that mature DN T cells from quad-deficient mice proliferate vigorously against both MHC-sufficient and MHC-deficient stimulator cells, but not in the absence of stimulator cells ([@B68]; [@B67]). In fact, a recent study has revealed the native self-protein CD155 as at least one of the ligands recognized by quad-deficient DN T cells via their TCR and in the absence of antigen-processing ([@B67]). Therefore, the quad-deficient mouse model has helped to demonstrate that DN T cell differentiation can proceed in the thymus and that DN T cell activation can occur independently of co-receptors.

Double negative T cells have not only been observed in quad-deficient mice. For instance, an increased number of DN T cells has been observed in many TCR transgenic models ([@B34]). In these TCR transgenic models, due to forced expression of an αβTCR transgene, the DN T cells do recognize peptide--MHC complexes in the absence of co-receptor expression, suggesting that they exhibit a high affinity for these antigenic complexes. Moreover, in the absence of CD28 co-stimulation which is required for clonal deletion of thymocytes ([@B54]; [@B37]; [@B42]), some thymocytes that strongly recognize self-ligands survive negative selection and ultimately develop into mature thymic DN T cells ([@B52]). Together, these results suggest that DN T cells may exhibit a relatively strong affinity toward their cognate ligands. This property is reminiscent of CD4^+^ Foxp3^+^ regulatory T cells (Tregs) and NKT cells, two immunoregulatory T cell subsets which undergo agonist selection in the thymus ([@B2]).

In addition to their distinct phenotype, DN T cells also exhibit a unique antigen-specific immunoregulatory potential. Indeed, the immunoregulatory function of DN T cells was first identified almost 25 years ago, when [@B63] successfully cloned DN T cells from mice and subsequently demonstrated that DN T cells mediate suppressor activity in a mixed-lymphocyte reaction (MLR). Subsequently, Dr. Zhang's group was the first to reveal the antigen-specific immunoregulatory potential of DN T cells ([@B86]). Specifically, they showed that DN T cells from 2C TCR transgenic mice suppress the proliferation and cytotoxic activity of 2C TCR CD8^+^ T cells *in vitro*, but not of CD8^+^ T cells carrying other antigen specificities ([@B86]; [@B79]). Moreover, the antigen-specific property of 2C TCR DN T cells is conferred, at least in part, by their ability to acquire peptide--MHC complexes from antigen presenting cells ([@B86]; [@B53]; [@B79]; [@B29]), a process known as trogocytosis ([@B36]). Notably, the *in vitro* antigen-specific suppressive activity of 2C TCR DN T cells toward CD8^+^ T cells was replicated using non-transgenic mice and humans ([@B86]; [@B79]; [@B25]). Together, these observations described a unique antigen-specific mode of immunoregulation provided by DN T cells, leading to the antigen-specific elimination of CD8^+^ T cells ([@B86]; [@B79]).

The immunoregulatory potential of DN T cells has since been shown to extend beyond T cells. Indeed, TCR transgenic and non-transgenic DN T cells can also inhibit NK cells ([@B32]; [@B64]), B cells ([@B84]; [@B33]; [@B28]), and dendritic cells ([@B30]). The combination of their distinct phenotypic characteristics and their unique antigen-specific immunoregulatory properties toward multiple cellular targets has prompted investigators to examine the role of DN T cells in various disease models. Herein, we will review the promising therapeutic potential of DN T cells in the context of various disease settings. More specifically, we will describe the impact of DN T cell transfer on the induction of graft tolerance and the prevention of autoimmunity as well as present their dual role in preventing graft-vs-host disease (GVHD) while promoting graft-vs-tumor (GvT) responses.

GRAFT TOLERANCE
===============

Although better known for their use in hematopoietic cell transplantation to establish donor chimerism or treat neoplastic relapse, donor leukocyte infusions (DLI) have also been shown to improve allograft survival after solid organ transplantation ([@B24]). Among possible mechanisms linking donor leukocyte transfer and allograft tolerance, DN T cells have been shown to increase allograft acceptance in various experimental settings. In an attempt to understand why DLI has a positive outcome on allograft survival, Dr. Zhang's group took advantage of the antigen-specific 2C TCR transgenic model ([@B73], [@B72]), where the 2C TCR is alloreactive to the L^d^ MHC class I molecule ([@B59]). Predictably, skin grafts bearing a single MHC-mismatch at L^d^ are thus rapidly rejected by the 2C TCR recipient mice due to the expression of L^d^ MHC class I molecule on the donor skin cells ([@B73], [@B72]; **Figure [1A](#F1){ref-type="fig"}**). However, the injection of donor spleen cells to the 2C TCR recipient mice prior to the skin graft efficiently induced antigen-specific allograft tolerance ([@B73], [@B72]; **Figure [1B](#F1){ref-type="fig"}**). The antigen-specific tolerance to skin allografts induced by the transfer of donor T cells was proposed to be mediated by 2C TCR transgenic DN T cells as only the 2C TCR transgenic DN T cell subset, but not the 2C CD4^+^ or 2C CD8^+^ T cell subset, was able to suppress an MLR response *in vitro* ([@B86]). Accordingly, Zhang's group showed that the injection of 2C TCR F1 DN T cell clones was sufficient to induce both prolonged survival of both skin and cardiac allografts ([@B86]; [@B10]; **Figure [1C](#F1){ref-type="fig"}**). Importantly, the allograft tolerance was antigen-specific, as full MHC-mismatched third party grafts were rapidly rejected ([@B86]; **Figure [1C](#F1){ref-type="fig"}**). Collectively, these data demonstrate that 2C DN T cells are sufficient to induce both skin and cardiac allograft survival, suggesting that immunoregulatory DN T cells contribute to the benefits of DLI on allograft survival.

![**Induction of allograft tolerance by the pre-transplantation infusion of donor-specific spleen cells or DN T cells**. This model takes advantage of the antigen-specific 2C TCR transgenic system and skin grafts to facilitate the study of allograft tolerance, where the 2C TCR transgene is alloreactive to the L^d^ MHC class I molecule. **(A)** C57BL/6 (H2^b^) mice are bred to BALB/c (H2^d^) mice to generate F1 mice (H2^b,d^) thus bearing the L^d^ MHC molecule (black mouse). C57BL/6 2C transgenic mice (H-2^b^) are bred to BALB/c (H2^*dm2*^) mice, which are a BALB/c L^d^ loss mutant (H2^d^, L^d-^; [@B58]), to generate 2CF1 mice (H2^b,d^, L^d-^) bearing the anti-L^d^ TCR (white mouse). Due to a single MHC-mismatch, skin grafts from L^d+^ F1 mice are rapidly rejected by the 2CF1 mice. **(B)** However, the transfer of donor spleen cells from L^d+^F1 mice to 2CF1 mice (L^d-^) prior to the L^d+^ skin graft transplantation results in graft survival. **(C)** Immunoregulatory 2C DN T cell clones obtained from 2CF1 TCR transgenic mice (L^d-^) prevent the rejection of single MHC-mismatch, allogeneic (L^d+^, in black) skin grafts. However, full MHC-mismatch, third party grafts (in gray) were rejected.](fimmu-04-00006-g001){#F1}

To further understand the mechanism by which 2C DN T cells promote antigen-specific allograft tolerance, [@B78] undertook the examination of the leukocytes found within the tolerated skin grafts. In doing so, they discovered that 2C DN T cells are the predominant leukocyte found within the accepted skin allografts. Moreover, the 2C DN T cells isolated from mice which had received donor spleen cells prior to the skin graft demonstrate an enhanced suppressive function toward 2C CD8^+^ T cells *in vitro* ([@B78]). Finally, the comparison of transcriptome profiles between 2C TCR F1 DN T cells clones that are able or unable to confer cardiac allograft tolerance revealed FcRγ as a potential molecule involved in defining the tolerogenic potential of 2C DN T cells ([@B40]). The importance of FcRγ expression on 2C DN T cells for the induction of allograft tolerance was confirmed as the adoptive transfer of FcRγ-sufficient, but not FcRγ-deficient, 2C DN T cells prior to transplantation increased skin allograft survival ([@B66]). Altogether, these results demonstrate that 2C DN T cells participate in allograft tolerance, likely by inhibiting pathogenic 2C CD8^+^ T cell responses, at least in the MHC class I-restricted graft tolerance model ([@B34]).

Importantly, these observations were not limited to the 2C TCR transgenic setting. Indeed, the injection of allogeneic donor spleen cells bearing a single MHC class I mismatch prior to skin transplantation in the non-transgenic setting also resulted in prolonged allograft survival ([@B72]; [@B78]; [@B85]). Analogous to the 2C TCR model, DN T cells from non-transgenic mice that are activated *in vivo* following the injection of donor spleen cells preferentially accumulate within the skin allograft and eliminate CD8^+^ T cells in an antigen-specific manner *in vitro* ([@B78]). In a full MHC-mismatch heart allograft, injection of non-transgenic DN T cells further promoted rapamycin-induced graft tolerance ([@B83]). In addition, *in vitro*-generated DN T cells can also provide antigen-specific skin and pancreatic islet allograft tolerance ([@B81], [@B82]). Moreover, with regards to xenografts, the injection of non-transgenic rat donor spleen cells in mice prevented CD4^+^ T cell-mediated cardiac xenograft rejection ([@B9], [@B11]). Similar to the transgenic setting, xenograft tolerance was induced by DN T cells, as the transfer of DN T cells that had been isolated from mice which had received xenogeneic donor spleen cells, was sufficient to ensure cardiac xenograft tolerance ([@B9]). In this xenogeneic model, DN T cells efficiently suppressed the proliferation of both CD4^+^ and CD8^+^ T cell anti-donor reactive cells ([@B9], [@B11]). Using a variant of this cardiac xenograft model, it was also shown that DN T cells can eliminate B cells, leading to a reduction in anti-donor-specific antibody levels and delayed graft rejection ([@B45]). Taken together, these findings suggest that, as opposed to the MHC class I-restricted 2C TCR DN T cells, DN T cells from non-transgenic mice can suppress CD4^+^ and CD8^+^ T cells as well as B cells in an antigen-specific manner and potently suppress both skin and cardiac allograft, as well as cardiac xenograft, rejection.

Fas--FasL interactions have been proposed as the molecular mechanism by which DN T cells eliminate anti-donor T cells, while the elimination of B cells is considered to be perforin-mediated ([@B86], [@B84]; [@B53]; [@B45]; [@B28]). Interestingly, an accumulation of DN T cells is observed in both Fas- and FasL-deficient mice ([@B70]; [@B65]), suggesting that the Fas--FasL pathway may regulate the number of DN T cells *in vivo*. By taking advantage of lpr mice, which exhibit a Fas-deficiency, [@B27] demonstrated that DN T cells from lpr mice can mediate their immunoregulatory function through the Fas pathway as long as the target T cells express a functional Fas protein. Indeed, DN T cells from lpr mice could effectively delay both single MHC class I- and single MHC class II-mismatched skin allograft rejection ([@B27]). In summary, DN T cells can clearly induce an antigen-specific tolerance to both allografts and xenografts by eliminating or inhibiting the function of various target immune cells.

AUTOIMMUNITY
============

The antigen-specific immunoregulatory potential of DN T cells in graft tolerance suggests that they may also participate in the induction of immune tolerance in various autoimmune settings. As a result, the role of DN T cells has been mostly explored in autoimmune lymphoproliferative syndrome (ALPS), systemic lupus erythematosus (SLE) and mouse models of type 1 diabetes (T1D), as described below.

AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME
---------------------------------------

Autoimmune lymphoproliferative syndrome is a rare disorder characterized by mutations in either Fas or FasL ([@B56]; [@B19]), which results in defective Fas-mediated apoptosis and, consequently, the abnormal accumulation of activated lymphocytes. ALPS patients on average present with a 10-fold increase in DN T cell proportion ([@B3]; [@B5]; [@B46]) and a sizeable proportion of DN T cells can also be found in the lymphoid organs of the murine models for ALPS, namely *lpr/lpr* (Fas-deficient) and *gld/gld* (FasL-deficient) mice ([@B12]; [@B70]; [@B65]). Moreover, a greater proportion of DN T cells from ALPS patients, in comparison to healthy controls, express the B cell antigen, B220 ([@B3]), which is consistent with findings in *lpr/lpr* mice ([@B18]). Accordingly, B220 expression is a general feature of proliferating T cells ([@B4]), which explains why B220^+^ DN T cells can also be found in healthy individuals. Although it cannot be denied that a drastic increase in the proportion of DN T cells can be observed in *lpr/lpr* and *gld/gld* mice, as well as ALPS patients, there is arguably no evidence to suggest that the accumulation of DN T cells is pathogenic. Indeed, Fas-deficient DN T cells found in *lpr/lpr* mice, but not FasL-deficient DN T cells found in *gld/gld* mice, remain functional and, as mentioned above, can efficiently induce graft tolerance ([@B27]). Hence, as DN T cell-mediated suppression depends on interactions between FasL on DN T cells and Fas on target T cells ([@B27]), it has been suggested that DN T cells accumulate in an attempt to compensate for their inability to suppress autoimmune T cells in *lpr/lpr* mice ([@B27]).

SYSTEMIC LUPUS ERYTHEMATOSUS
----------------------------

Similar to ALPS patients, DN T cells are also found in greater numbers in the peripheral blood of patients with SLE ([@B16]). However, in the case of SLE, these DN T cells are major producers of IL-17 ([@B17]), which is pathogenic in this disease ([@B71]; [@B21]). Moreover, IL-17-producing DN T cells can be found in the kidney sections of patients with lupus nephritis ([@B16]). These results lead [@B16] to suggest that DN T cells themselves are pathogenic in SLE. Yet, it must be noted that, in these studies, DN T cells were defined as CD4^-^CD8^-^TCRαβ^+^ cells, which may contain contaminating CD4^-^CD8^-^ NKT cells expressing a TCR restricted to CD1d molecules ([@B34]). Of relevance, NKT cells do indeed include a subset of CD4^-^NK1.1^-^ IL-17-producing cells ([@B13]). Moreover, NKT cells have been implicated in SLE pathogenesis where the activation of NKT cells through the administration of α-GalCer exacerbated disease whereas the inhibition of NKT cell activation using an anti-CD1d blocking antibody resulted in disease amelioration ([@B80]). Thus, NKT cells cannot be ruled out as the true IL-17-producing cell subset in this particular study. Nevertheless, IL-17-producing DN T cells have also been shown to play a protective role against bacterial infections ([@B14]; [@B57]). Altogether, an uncertain, yet possible, role for DN T cells in patients with SLE remains to be defined.

TYPE 1 DIABETES
---------------

Type 1 diabetes occurs as a result of the antigen-specific elimination of pancreatic insulin-producing β cells. It thus presents as a relevant model to investigate the antigen-specific immunoregulatory potential of DN T cells.

The tolerogenic role of DN T cells in the prevention of T1D was first revealed using the P14/RIP-gp transgenic mouse model ([@B49]), where the MHC class I-restricted P14 TCR transgene recognizes the lymphocytic choriomeningitis virus (LCMV) protein, gp33--41 (gp33), which is expressed under the rat insulin promoter (RIP) forcing its expression in the pancreatic tissue. RIP-gp mice that are crossed to P14 mice carry a very high percentage of gp33-reactive T cells, yet the resulting P14 TCR:RIP-gp mice do not spontaneously develop diabetes on the C57BL/6 background ([@B49]). Indeed, P14/RIP-gp transgenic mice rapidly develop diabetes upon treatment with gp33 peptide and anti-CD40 agonistic antibody, which results in the infiltration of pancreatic islets by activated CD8^+^ T cells and the subsequent destruction of the insulin-producing β cells ([@B31]). Using this model, it was shown that the transfer of gp33 activated P14 DN T cells 1 day prior to diabetes induction can inhibit diabetes development ([@B26]). These results were the first indication that DN T cells may participate in the prevention of a CD8^+^ T cell-driven T1D pathology, further lending support for a potential role for DN T cells toward the elimination of CD8^+^ T cells *in vivo*.

The protective role of DN T cells in diabetes development was further investigated by our group using the 3A9 TCR:insHEL transgenic system, in which the MHC class II-restricted 3A9 TCR transgene recognizes a peptide from hen egg lysozyme (HEL) presented by I-A^k^, while the insHEL transgene forces the expression of HEL in the pancreatic tissue. Although TCR:insHEL BALB.K mice are relatively resistant to T1D, CD47-deficient TCR:insHEL BALB.K mice have a high and spontaneous incidence of diabetes. Using this model of spontaneous T1D, a single transfer of 3A9 DN T cells in the TCR:insHEL CD47-deficient BALB.K transgenic model was able to significantly inhibit the development of T1D ([@B22]). Notably, a 3A9 DN T cell transfer led to a significant reduction in antigen-specific autoantibody serum levels ([@B22]), suggesting the *in vivo* elimination of autoreactive B cells. We subsequently demonstrated that 3A9 DN T cells efficiently eliminate HEL-loaded B cells *in vitro* ([@B33]). Although this model is imperfect in that it is a CD47-deficient model, where CD47 is implicated in apoptosis, phagocytosis, cell migration, and T cell responses ([@B50]; [@B8]), it is nevertheless a spontaneous model of T1D wherein the results complement the findings of [@B26] suggesting that DN T cells may be of therapeutic interest for T1D.

Interestingly, the proportion of DN T cells is significantly reduced in diabetes-prone mice in comparison to diabetes-resistant mice in both the transgenic and non-transgenic systems ([@B22]). It is of relevance that both the non-transgenic and TCR:insHEL transgenic diabetes-prone non-obese diabetic (NOD) mouse models exhibit a low number of DN T cells relative to other diabetes-resistant strains as it suggests that low DN T cell numbers are associated with diabetes susceptibility. Despite a reduction in cell number, 3A9 DN T cells from 3A9 TCR transgenic NOD. H2^*k*^ mice carrying a diabetes-prone genetic background ([@B43]) exhibit an equally potent cytotoxic function in comparison to 3A9 DN T cells from diabetes-resistant 3A9 TCR transgenic B10.Br mice ([@B33]). Therefore, the association of DN T cells with diabetes susceptibility is due to a deficiency in DN T cell number rather than function. Altogether, these results further suggest that the restoration of DN T cell number can prevent T1D development in otherwise diabetes-susceptible mice.

The role of DN T cells in the prevention of T1D was also recently evaluated using non-transgenic DN T cells. Indeed, [@B23] have demonstrated that non-transgenic DN T cells can protect from autoimmune diabetes. Specifically, diabetes induction was inhibited if DN T cells were transferred into recipient NOD.SCID (severe combined immunodeficiency) mice 1 month prior to co-infusion with diabetogenic spleen cells, whereas the simultaneous co-infusion of diabetogenic spleen cells and DN T cells does not protect from disease ([@B23]). However, as NKT cells were not fully excluded from the cellular preparation, additional studies using NKT cell-depleted non-transgenic DN T cells are warranted to firmly establish the biological function of these cells in the prevention of autoimmune diabetes in diabetes-susceptible NOD mice. Notably, further investigation is still needed to verify the role of DN T cells in T1D development using non-lymphopenic NOD mice, thus under more physiological and spontaneous conditions. Nevertheless, these results do provide useful information regarding the critical time of treatment initiation as well as evidence that non-transgenic DN T cells may exhibit the potential to inhibit T1D development in non-transgenic mice.

A more recent study further evaluated the role of non-transgenic DN T cells in T1D. Here, it was shown that 50% of CD4^+^ T cells isolated from an MLR had been converted to CD4^-^CD8^-^ T cells. These CD4^+^ T cell-converted DN T cells sorted by flow cytometry were shown to delay T1D onset when adoptively transferred to NOD.SCID mice in combination with diabetogenic T cells ([@B82]). This delay was further enhanced when using GAD65 antigen to stimulate the CD4^+^ T cells, thereby likely generating a higher proportion of GAD65-specific DN T cells. Moreover, a single transfer of GAD65-specific DN T cells specificity was able to prevent diabetes development in 5-week-old NOD mice and decrease blood glucose levels in new-onset diabetic NOD mice ([@B82]). Therefore, this study offers a potentially translatable therapeutic approach for the generation of antigen-specific DNT cells in the prevention and treatment of T1D.

Altogether, these findings point toward an antigen-specific immunoregulatory role for DN T cells in autoimmune diseases. The therapeutic potential of these cells certainly merits further investigation in additional pre-clinical models.

GRAFT-vs-HOST DISEASE AND CANCER
================================

In the treatment of hematological malignancies, allogeneic hematopoietic cell transplantation (AHCT) can eradicate several blood cancers that are incurable by chemotherapy alone. Despite indisputable successes, the efficacy of AHCT is still limited by cancer recurrence and the development of GVHD ([@B55]). While the acute form of GVHD is triggered by direct T cell recognition of histocompatibility antigens, the pathophysiology of chronic GVHD remains more elusive and relies on several immune cell types ([@B61]). Currently, 40--80% of patients develop chronic GVHD after AHCT, which brings substantial morbidity and mortality ([@B41]). Several lines of evidence suggest that immunoregulatory immune cells are paramount to GVHD prevention. Indeed, both CD4^+^ Tregs and NKT cells have been suggested as major contributors of allotolerance in hematopoietic cell transplantation ([@B35]; [@B38]; [@B20]; [@B7]). However, the ability of Tregs to maintain their anti-tumor T cell responses remains controversial ([@B51]; [@B60]; [@B44]; [@B62]; [@B38]). Here, we review the potential of DN T cells at inhibiting GVHD while specifically promoting anti-tumor responses.

GRAFT-vs-HOST DISEASE
---------------------

Mouse models of GVHD, although they admittedly do not fully replicate human disease, facilitate the examination of the cellular process amid the allogeneic responses which give rise to a GVHD-like pathology *in vivo* ([@B61]). A potential role for DN T cells in the prevention of GVHD can be traced back to over two decades ago when [@B6] demonstrated that transfer of spleen cells from pre-immunized mice was able to inhibit GVHD only when DN T cells were included in the cellular preparations. Although the DN T cells were not void of contaminating NKT cells, these results still suggested that DN T cells play a role in GVHD prevention. Because of their prominent antigen-specific immunoregulatory potential as well as their ability to promote allotolerance, the contribution of DN T cells at preventing GVHD was later investigated using the 2C TCR single MHC-mismatch model ([@B75]), for which DN T cells have been shown to effectively prevent allograft rejection ([@B86]; [@B78]; [@B10]; **Figure [1](#F1){ref-type="fig"}**). Specifically, mice bearing a single MHC-mismatch (L^d^) injected with L^d^-specific 2C TCR transgenic spleen cells survived for more than 150 days without any clinical or histological signs of acute or chronic GVHD ([@B75]; **Figure [2A](#F2){ref-type="fig"}**). The tolerance of donor spleen cells may be explained, at least in part, by the accumulation of 2C TCR DN T cells, which can effectively inhibit pathogenic CD8^+^ T cell responses, in recipient mice ([@B75]). Subsequently, the role of non-transgenic DN T cells in both parent to F1 and fully MHC-mismatched bone marrow (BM) transplantation following either a myeloablative ([@B32]) or non-myeloablative regimen ([@B64]) was investigated (**Figure [2B](#F2){ref-type="fig"}**). In stark contrast to CD4^+^ and CD8^+^ T cells, the co-injection of non-transgenic DN T cells with T cell-depleted BM into a sublethally irradiated host ensured prolonged recipient survival in the absence of clinical signs of GVHD ([@B32]; [@B64]; **Figure [2B](#F2){ref-type="fig"}**), indicating that DN T cells are not alloreactive nor pathogenic in this context. Moreover, this led to stable mixed chimerism and, as opposed to BM transplantation alone, promoted donor allotolerance ([@B32]; [@B64]; **Figure [2B](#F2){ref-type="fig"}**). Together, these findings demonstrate that, as opposed to CD4^+^ or CD8^+^ T cells, the transfer of allogeneic DN T cells does not cause GVHD. Rather, DN T cells prevent GVHD, induce mixed chimerism and promote donor-specific allotolerance.

![**Double negative T cells promote tolerance while inhibiting GVHD**. **(A)** Immunodeficient SCID F1 mice (H2^b,d^, L^d+^) were sublethally irradiated and reconstituted with 2CF1 (H2^b,dm2^, L^d-^) L^d^-specific spleen cells. Three weeks later, recipient mice were given skin grafts from F1 (L^d+^, in white) and full MHC-mismatch, third party (in gray) mice. The third party skin graft was rejected, whereas the skin graft from the F1 (L^d+^) donor mouse was accepted. Importantly, the recipient mice showed no signs of GVHD and exhibited a prominent increase in the levels of donor-derived DN T cells over time. **(B)** BALB/c (H2^d^) mice underwent myeloablative (*top panel*, sublethal irradiation) or non-myeloablative (*bottom panel*, busulfan treatment) conditioning prior to being reconstituted with a combination of C57BL/6 (H2^b^) DN T cells and T cell-depleted (TCD) C57BL/6 (H2^b^) bone marrow (BM) cells. Subsequently, recipient mice received skin grafts from donor C57BL/6 (H2^b^, in black) and third party (H2^k^, in gray) mice. Regardless of the type of conditioning regimen utilized, the recipient mice accepted all C57BL/6 (H2^b^, in black) donor grafts while third party (H2^k^, in gray) grafts were rejected.](fimmu-04-00006-g002){#F2}

Notably, there is accrued evidence that DN T cells also prevent GVHD in humans upon AHCT. Indeed, the stem cells used for AHCT are currently most commonly obtained from the peripheral blood mononuclear cells of granulocyte colony-stimulating factor (G-CSF)-treated donors, where G-CSF is used to mobilize CD34^+^ hematopoietic stem cells into the blood ([@B61]). Interestingly, in addition to skewing toward a Th2 phenotype, G-CSF treatment also results in an increase in the proportion of immunoregulatory DN T cells in the blood ([@B39]). The combination of these two phenotypes may explain why the transfer of CD34^+^ stem cells isolated following G-CSF treatment does not increase the incidence of acute GVHD relative to classical BM transplants. More recently, two studies also noted a clear correlation between an elevated proportion of DN T cells and a low incidence of GVHD development following AHCT ([@B47]; [@B74]). Together, these observations support the view that human DN T cells may prevent GVHD.

THE ANTI-TUMOR RESPONSE
-----------------------

In addition to preventing GVHD, DN T cells demonstrate an anti-tumor activity without causing GVHD in recipient mice ([@B77], [@B76]). Indeed, \>90% of sublethally irradiated immunodeficient SCID mice that were co-infused with a lethal dose of A20 lymphoma cells together with allogeneic 2C TCR transgenic spleen cells survived indefinitely in the absence of GVHD. Interestingly, recipient mice exhibited a 15-fold increase in the number of DN T cells in their spleen ([@B76]), suggesting an association between DN T cells and the inhibition of GVHD as well as tumor growth. Accordingly, [@B76] demonstrated that the injection of either 2C DN T cell clones or non-transgenic DN T cells was sufficient to prevent A20 lymphoma tumor growth, without inducing clinical or histological signs of GVHD. Altogether, these results further demonstrate the anti-tumoral potential of DN T cells.

To further define the potential use of DN T cells in the treatment of hematological malignancies, [@B48] performed a pre-clinical study in acute myeloid leukemia (AML) patients undergoing complete remission following standard chemotherapy. In this study, they demonstrate that DN T cells can be readily isolated from the blood of AML patients. Moreover, the isolated DN T cells maintain their phenotype following a proficient cellular expansion reaching nearly 500-fold in 2 weeks ([@B48]). Of interest, the DN T cells isolated and expanded *in vitro* demonstrated efficient cytolytic activity toward the autologous leukemic cells in six out of seven patients ([@B48]). Importantly, the anti-tumoral activity of DN T cells may extend beyond hematological malignancies, as melanoma-reactive DN T cells have also been successfully isolated from a previously immunized melanoma patient ([@B69]). The mechanism by which DN T cells are able to confer antigen-specific immune tolerance all the while providing an anti-tumor response is counterintuitive and certainly merits further investigation.

CONCLUSION
==========

Immunoregulatory DN T cells, which compose approximately 1--3% of T cells in human PBMCs ([@B25]), demonstrate a unique antigen-specific therapeutic potential, such that they provide a favorable outcome in graft tolerance, autoimmunity and GVHD. In addition, DN T cells exhibit an interesting anti-tumoral potential. This seemingly broad applicability of DN T cells at conferring antigen-specific immune tolerance must be interpreted with caution. Indeed, DN T cells compose a heterogeneous subset of cells, which include all CD4^-^CD8^-^CD3^+^ T cell subsets, namely TCRγδ T cells, NKT cells and immunoregulatory TCRαβ DN T cells ([@B34]). Despite the heterogeneity in the description of DN T cells in various studies, which do not always exclude TCRγδ and/or NKT cells, most studies in TCR transgenic and non-transgenic mice as well as in humans point toward an immunoregulatory role for DN T cells. A few notable exceptions to this are the description of pathogenic IL-17-producing DN T cells in SLE ([@B17]) and the characterization of IL-23 responsive DN T cells controlling bacterial infections ([@B14], [@B15]; [@B57]). Clearly, additional studies aimed at identifying unique markers for these unique cell types will help clarify which specific cellular subset contributes to each specific biological setting.

In conclusion, immunoregulatory DN T cells exhibit great potential as a cellular therapy for various models of disease, with exciting advances in the pre-clinical setting. As the function of DN T cells is mainly antigen-specific, the use of DN T cells in immunotherapy should lead to fewer side-effects and a decreased risk of infections, which is a major concern in the application of broad immunosuppressive regimens. Moreover, DN T cells exhibit a potent immunosuppressive potential in multiple model systems, from transplantation to autoimmunity, suggesting a vast array of applicability of DN T cells in cellular therapy.
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